ACTIVE_NOT_RECRUITING

Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Purpose is to study the clinical outcomes of Clareon Vivity and Clareon Vivity Toric intraocular lens (IOL) implants in patients who are planning to have cataract surgery in both eyes with a mini-monovision approach.

Official Title

Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach

Quick Facts

Study Start:2023-04-06

Study Completion:2026-06

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05821101

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Adult patients with bilateral age-related visually significant cataracts in otherwise healthy eyes, undergoing bilateral sequential implantation within 21 days using Clareon Vivity and Clareon Vivity Torics * IOL powers between +10D to +30.0D, T3-T6 * Potential acuity measured post-operatively 20/25 or better in both eyes	* History of ocular or refractive surgery * Ocular or systemic comorbidities that may alter or reduce visual acuity, contrast sensitivity, binocularity, or impair reading performance such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, strabismus/amblyopia etc. * Patients with irregular astigmatism, corneal dystrophies, pupil abnormalities, zonular laxity * Intraoperative or postoperative complications

Inclusion Criteria

Exclusion Criteria

* Adult patients with bilateral age-related visually significant cataracts in otherwise healthy eyes, undergoing bilateral sequential implantation within 21 days using Clareon Vivity and Clareon Vivity Torics
* IOL powers between +10D to +30.0D, T3-T6
* Potential acuity measured post-operatively 20/25 or better in both eyes

* History of ocular or refractive surgery
* Ocular or systemic comorbidities that may alter or reduce visual acuity, contrast sensitivity, binocularity, or impair reading performance such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, strabismus/amblyopia etc.
* Patients with irregular astigmatism, corneal dystrophies, pupil abnormalities, zonular laxity
* Intraoperative or postoperative complications

Contacts and Locations

Study Locations (Sites)

Palo Alto Medical Foundation

Palo Alto, California, 94301

United States

Collaborators and Investigators

Sponsor: Debbie S. Kuo, MD

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-06

Study Completion Date2026-06

Study Record Updates

Study Start Date2023-04-06

Study Completion Date2026-06

Terms related to this study

Additional Relevant MeSH Terms

Aphakia, Postcataract